JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1988; 12:507-513
© 1988 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wyse, D.
Right arrow Articles by Rademaker, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wyse, D.
Right arrow Articles by Rademaker, A.

Prophylactic versus selective lidocaine for early ventricular arrhythmias of myocardial infarction

DG Wyse, J Kellen, and AW Rademaker

Department of Medicine, University of Calgary, Alberta, Canada.

A total of 333 patients arriving within 6 h of the onset of suspected or proven but uncomplicated myocardial infarction were randomized to treatment by either the prophylactic or the selective lidocaine strategy. Patients were monitored for 24 h. The major end points were sustained ventricular tachycardia or fibrillation and emergent adverse effects of lidocaine. There were four episodes of emergent adverse effects of lidocaine, all in patients treated by the prophylactic strategy (2.4%, p = NS). There were two episodes of nonagonal, sustained ventricular tachycardia or fibrillation, both in patients treated by the selective strategy (1.2%, p = NS). The difference between major end points was 1.2% in favor of the selective strategy (p = NS). There were significant differences in lesser ventricular arrhythmias and lesser lidocaine adverse effects but no difference in mortality rate (selective = 3%, prophylactic = 5%, p = NS). Potentially lethal ventricular arrhythmias occurred only in patients with myocardial infarction. Nonlethal but complex ventricular arrhythmias were rare in patients without infarction. However, toxicity occurred in patients with and without infarction. The major conclusion of this study is that there is no important overall advantage of either strategy for lidocaine use in such patients. The advantage of one is the risk of the other. The strategy used should be selected for individual patients, and the use of one strategy for all patients would seem inappropriate.


This article has been cited by other articles:


Home page
CirculationHome page
Part 5: Acute Coronary Syndromes
Circulation, November 29, 2005; 112(22_suppl): III-55 - III-72.
[Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1988 by the American College of Cardiology Foundation.